Central Nervous System (CNS)

Challenge: Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The asset in question was a...

Challenge: A former venture fund client identified a novel Phase 1-ready asset for treating a rare CNS infectious disease and was interested in licensing the asset and founding a new company to...

Challenge: A venture capital portfolio company developing small molecule therapeutics for metabolic/obesity indications had made the strategic decision to supplement their internal product pipeline...

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...

Challenge: A leading private US academic institution had created a therapeutics accelerator program to support early discoveries and facilitate industry partnerships of its assets. One of its...

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...

Challenge: A VC firm was interested in a US-based drug repurposing company and asked Alacrita to perform a high level technical due diligence exercise to help the firm make an informed decision about...

Challenge: A clinical stage biotech company developing treatments for Alzheimer's disease was looking for a valuation of its Phase II-ready therapeutic drug. The drug was a re-purposed combination of...

Challenge: Our client was working with a family office which had invested in a novel IV formulation of a repurposed asset for the treatment of ischemic stroke. With a promising completed phase II...

Challenge: A clinical stage company developed two series of small molecules to treat Alzheimer Disease (AD) and other central nervous system (CNS) indications. Their lead asset aims for symptomatic...

Challenge: A private equity fund approaching an investment in a Phase III asset required an expert evaluation of the likelihood of success in the Phase III trial. The molecule, targeted at two CNS...